Design Of Primer And Probe To Detect SNP Rs 1892901 In Fosl-1Gene In Different Types Of Cancer In Iraqi Population

Abstract

Safa Ahmed Abed, Hiba Muneer Al-Khafaji.

It has been shown that the etiology of thyroid, breast and prostate cancer is associated with hereditary and some environmental factors that cause damage to DNA. Protein coding genes are responsible for the development of protein and thus have been reported to be good candidate susceptibility genes for thyroid, breast and prostate cancer. (FOSL1) proteins have important functions in the growth, including the regulation of cell proliferation, differentiation and transformation. There have been studies of elevated levels of FOSL1 in cancers. However, the available methods for measuring FOSL1 levels are direct and quantitative using Poly Chain Reaction (RT-PCR) in real time. In the present study, whole blood was isolated from 100 individuals distributed into four groups as follows: Group 1 included: 25 samples from thyroid cancer patients; Group 2: 25 samples from breast cancer patients; Group 3: 25 samples from prostate cancer and Group 4:25 samples from apparently healthy individuals. The messenger RNA (mRNA) expression levels of FOSL_1in the peripheral blood was analyzed using reverse transcription polymerase chain reaction (RT PCR). The expression of FOSL_1 mRNA in the fold of gene expression in prostatic cancer group was 4 time higher than that of healthy group. That for the breast cancer group was 3 times higher than the healthy group and the thyroid cancer group was 3 times higher than the healthy group., respectively, Using GAPDH as Housekeeping Gene. In conclusion, there is an important link between blood and tumor tissue expression of FOSL1 gene. in thyroid, breast and prostate cancer, could allow the introduction in clinical practice of a simple test that would measure mRNA levels of DNA protein coding genes in peripheral blood samples instead of tissue samples; thus justifying its use as a prognostic and predictive factors in thyroid, breast and prostate cancer patients.